Skip to content
Signal Bureau What’s happening · what the record shows

FDA

U.S. Food and Drug Administration — The U.S. regulator that approves drugs, medical devices, and food safety.

Coverage of FDA is rising : 51 signals on the latest tracked day, up 143% from its three-week baseline of 21, across 10 domains (up from 6 a week ago). That makes it the #16 most-covered of the 274 concerns we track.

If FDA matters to your work, coverage is climbing off its baseline — worth a closer-than-usual look this week.

What’s changed

7 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.

What the reporting says

Across 711 tracked stories from 52 outlets, reporting on FDA most often describes regulatory approvals (408), IPOs or listings (6), military action (5), launches or releases (4), acquisition (4), meetings or visits (4).

It shows up alongside GLP-1 (17), Eli Lilly (24), Immunotherapy (39), United States (39), Colorectal Cancer (37), Merck (16), Pfizer (14), AI (24).

Two steps out: China (through United States, 39 shared stories on the weaker link); Hormuz (through United States, 39 shared stories on the weaker link); Iran (through United States, 39 shared stories on the weaker link); Israel (through United States, 39 shared stories on the weaker link).

Tracked since Apr 6, with coverage on 94 separate days — concentrated in Pharma Regulatory and Biotech Pharma.

What the crowd is pricing

Coverage momentum and market odds are separate readings — one can move without the other. A price is what the crowd believes, shown as a signal, not a forecast of ours.
Ask the engine about FDA + Track FDA for a daily read
Counts computed from our committed signal record (Jun 24 – Aug 8, 44 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 8, 8:10 PM PT